The FDA approved epcoritamab-bysp as a monotherapy or with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved epcoritamab-bysp (Epkinly) with lenalidomide (Revlimid) and rituximab...
Many doctors don’t prescribe hormone therapy in women with gynecologic cancers, and cancer-related crowdfunding often falls short of goals.
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) for certain adults with HER2-positive breast cancer. Pertuzumab-dpzb...
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible NPM1 mutations. The U.S. Food and Drug Administration (FDA) has approved the use of the...
Former U.S. Olympic Field Hockey player and cancer survivor Karlie Kisha is running the Philadelphia Marathon to raise money for research.
More people with breast cancer can forgo radiation after surgery, and a treatment combination helps control esophageal cancer.
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) as...
De-escalating treatment for patients with chronic cancers can be beneficial for overall mental health. Patients with chronic lymphocytic leukemia (CLL) are typically treated with Bruton’s tyrosine kinase inhibitors, or BTKis. Although effective, patients typically...
The FDA is proposing a cap on nicotine in cigarettes that would reduce the amount by 95%, which could help to save millions of lives.
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More